Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Kluisbergen – page 85

2 297 clinical trials in Kluisbergen, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Kluisbergen at a glance
2 297
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 297 trials in Kluisbergen

Open in trial search

Ischaemic stroke

Not yet recruiting

Effectiveness of Tenecteplase in Acute Ischemic Stroke Patients Treated 4.5–24 Hours After Onset Before Transfer for Thrombectomy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tenecteplase
  • Sponsor:Hopital Fondation Adolphe De Rothschild

Anxiety

Not yet recruiting

Efficacy of Etifoxine in Adults with Adjustment Disorder with Anxiety: A Randomized, Double‑Blind, Placebo‑Controlled Trial

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Etifoxine Hydrochloride
  • Sponsor:Biocodex

Chondrosarcoma+2

Not yet recruiting

Phase I/II Study of Dinutuximab Beta, Irinotecan, and Sirolimus in Children, Adolescents, and Adults with Relapsed or Refractory Bone Sarcoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Dinutuximab Beta
  • Sponsor:Les Hopitaux Universitaires De Strasbourg

Stargardt's disease

Not yet recruiting

Phase 3 Study of Gildeuretinol Acetate (ALK‑001) to Assess Safety and Efficacy in Slowing Progression of Stargardt Disease in Adults

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Gildeuretinol acetate
  • Sponsor:Alkeus Pharmaceuticals Inc.

Interstitial lung disease

Not yet recruiting

Immunomodulatory Treatment with Prednisone, Azithromycin and Hydroxychloroquine in Patients with Surfactant‑Related Gene Mutation Interstitial Lung Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azithromycin
  • Sponsor:Assistance Publique Hopitaux De Paris

Bacterial sepsis

Not yet recruiting

Individualized beta‑lactam dosing with piperacillin (drug combination) for ICU patients with sepsis caused by gram‑negative bacteria

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:Centre Hospitalier Universitaire De Rennes

Efficacy of Prednisolone Metasulfobenzoate Sodium vs Placebo in Adults with Fibrotic Hypersensitivity Pneumonitis: A Randomized Controlled Trial

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone Metasulfobenzoate Sodium
  • Sponsor:Assistance Publique Hopitaux De Paris

Two dosing schedules of the herpes zoster vaccine (recombinant varicella zoster virus glycoprotein E) in MS and NMOSD patients on rituximab or ocrelizumab

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Systemic scleroderma

Not yet recruiting

Safety and efficacy of obinutuzumab in patients with active diffuse systemic sclerosis: a randomized, double-blind, placebo-controlled trial

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Disease risk factor+1

Not yet recruiting

Colchicine for Reducing Dependency and Vascular Events in Patients After Acute Intracerebral Hemorrhage

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Hamilton Health Sciences Corporation

Breast cancer

Not yet recruiting

Evaluation of Cefazolin versus Placebo for Preventing Surgical Site Infection in Breast Cancer Lumpectomy Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cefazolin Sodium
  • Sponsor:University Hospital Of Clermont-Ferrand

Obinutuzumab in patients with pure class V lupus nephritis (systemic lupus erythematosus membranous nephropathy) – phase II trial

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Kluisbergen

What the registry says about research in the country

01 Respiratory Virus Research

Comprehensive studies focusing on respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) prevention in older adults. Researchers are evaluating innovative vaccine approaches for these common respiratory pathogens.

  • RSV Vaccine Development
  • Co-administration Studies
  • Elderly Population Protection

Multiple trials are examining vaccine effectiveness and immune responses in adults over 60 years of age.

02 Influenza Prevention

Research examining a novel influenza vaccine in both younger and older adult populations. The studies focus on safety assessment and immune system response evaluation.

  • Vaccine Safety Analysis
  • Immune Response Measurement
  • Cross-age Group Studies

Trials aim to establish optimal dosing while ensuring robust protection against influenza.

03 Urinary Health Initiatives

Clinical research targeting urinary tract infections (UTI), with particular attention to prevention through vaccination. Studies include both male and female participants aged 18-64.

  • UTI Prevention
  • E. coli-specific Protection
  • Vaccine Safety Evaluation

The research focuses on developing preventive measures against common bacterial infections.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.